Literature DB >> 3325704

[Chronic disseminated histoplasmosis as an opportunistic infection].

R Negroni1, A Arechavala, A M Robles.   

Abstract

Sixty four patients suffering a chronic disseminated histoplasmosis were studied with the aim of fingind if they had predisposing factors. Thirty cases (46.8%) presented the following predisposing conditions: long treatment with low doses of corticosteroids in 7, ethilic hepatopathy in 7, diabetes in 4, lymphoma in 3, epitheliomas in 3, epitheliomas and diabetes in 1, renal insufficiency in 1, toxic hepatitis in 1, radiations in 1, long treatment with psychotropics in 1 and primary combined immunodeficiency in 1. Only slight differences were detected between these two groups of patients; those who exhibited predisposing factors presented an increased number of clinical localizations, altered cell mediated immunological tests were more frequent as well as the number of patients with multiple relapses and deaths. Histoplasmosis was not the cause of death in any case. It is possible that if a more frequent aggressive exploration, as hepatic biopsy, would be done a higher number of patients with predisposing factors would have been demonstrated.

Entities:  

Mesh:

Year:  1987        PMID: 3325704

Source DB:  PubMed          Journal:  Med Cutan Ibero Lat Am        ISSN: 0210-5187


  3 in total

1.  Treatment of disseminated histoplasmosis in hamsters.

Authors:  J L Finquelievich; R Negroni; C Iovannitti; A J Bava
Journal:  Mycopathologia       Date:  1989-02       Impact factor: 2.574

Review 2.  Perforation of the nasal septum as the first sign of histoplasmosis associated with AIDS and review of published literature.

Authors:  Angel Jaimes; Sandra Muvdi; Zulma Alvarado; Gerzaín Rodríguez
Journal:  Mycopathologia       Date:  2013-05-10       Impact factor: 2.574

Review 3.  A practical guide to large-scale docking.

Authors:  Brian J Bender; Stefan Gahbauer; Andreas Luttens; Jiankun Lyu; Chase M Webb; Reed M Stein; Elissa A Fink; Trent E Balius; Jens Carlsson; John J Irwin; Brian K Shoichet
Journal:  Nat Protoc       Date:  2021-09-24       Impact factor: 17.021

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.